Lexeo Therapeutics
Focus: Lexeo Therapeutics is a gene therapy biotech focused on rare and neurodegenerative diseases, headquartered in New York with early-stage clinical programs.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Open Jobs
7+1 this month
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Should You Work at Lexeo Therapeutics?
AI assessmentEarly-stage gene therapy bet for scientists seeking cutting-edge research and upside potential, but career stability dependent on clinical trial success and capital markets sentiment.
Why Work Here
- Early-stage gene therapy platform with multiple Phase 1/2 programs targeting underserved rare diseases like Friedreich Ataxia and Arrhythmogenic Cardiomyopathy.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients Wi
Arrhythmogenic CardiomyopathyClinical Trials (1)
NCT06976606A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
N/AHelp build intelligence for Lexeo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.